Clinical Trial Update: A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating 4 versus 6 cycles of CHP in combination with Polatuzumab vedotin and Rituximab for previously untreated diffuse large B-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Cyclophosphamide (Cytoxan) (cyclophosphamide)
• Doxorubicin (Adriamycin) (doxorubicin)
• Prednisone (Deltasone) (prednisone)
• Rituximab (Rituxan) (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING